A Comparative Study of the Market Configuration of the Japanese Pharmaceutical Market Using the Gini Coefficient and Herfindahl–Hirschman Index
Authors:
- 27 January 2020
- journal article
- research article
- Published by Springer Nature in Therapeutic Innovation & Regulatory Science
- Vol. 54 (5) , 1047-1055
Abstract
As of 2015, the Japanese pharmaceutical market was the world’s third largest pharmaceutical market. Although previous studies have examined market differences in terms of market size and pricing policy, little is known about comparative market configurations. The present study provides a comparative analysis of pharmaceutical market configurations in Japan and five other markets.Keywords
This publication has 14 references indexed in Scilit:
- Differential Pricing of Pharmaceuticals: Theory, Evidence and Emerging IssuesPharmacoEconomics, 2018
- The pharmaceutical market and drug development prognosis in Japan: Current and future perspectives according to pharmacological classesJournal of Generic Medicines, 2017
- Drugs Targeted for Price Cutting in Japan: The Case of Price Revisions Based on the Divergence of Official Versus Delivery PricesTherapeutic Innovation & Regulatory Science, 2017
- Comparative Analysis Between the Top-Selling Drugs in the Japanese Pharmaceutical Market and Those in the United States, the United Kingdom, France, and GermanyTherapeutic Innovation & Regulatory Science, 2016
- Impact of Premium Rewards for the Promotion of Innovative Drug Discovery on the Japanese Pharmaceutical Market: An Analysis by Therapeutic AreaTherapeutic Innovation & Regulatory Science, 2016
- Factors That Affect the Acquisition of Reward Premiums for Promotion of Innovative Drug Discovery in JapanTherapeutic Innovation & Regulatory Science, 2016
- The effect of centralization of health care services on travel time and its equalityHealth Policy, 2015
- Prices and distribution margins of in-patent drugs in pharmacy: A comparison in seven European countriesHealth Policy, 2007
- Pharmaceutical Price Controls and Entry StrategiesReview of Economics and Statistics, 2007
- Cross-national price differences for pharmaceuticals: how large, and why?Journal of Health Economics, 2000